Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Erasca, Inc. stock logo
ERAS
Erasca
$1.54
+5.5%
$1.38
$1.01
$3.45
$436.27M1.051.67 million shs1.44 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$5.28
+6.2%
$4.13
$2.22
$6.19
$451.55M1.03658,964 shs1.14 million shs
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
$0.00
$0.50
$1.86
$105.76MN/A71,826 shs50,100 shs
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
$17.25
+6.0%
$16.79
$11.56
$29.79
$442.98M2313,125 shs210,429 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Erasca, Inc. stock logo
ERAS
Erasca
+2.82%+7.35%-8.75%+22.18%-37.87%
Rezolute, Inc. stock logo
RZLT
Rezolute
-0.20%+12.44%+12.19%+84.07%+19.76%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00%0.00%0.00%0.00%0.00%
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
+2.01%+2.84%-15.52%+30.45%+22.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Erasca, Inc. stock logo
ERAS
Erasca
2.06 of 5 stars
3.51.00.00.01.12.50.6
Rezolute, Inc. stock logo
RZLT
Rezolute
2.2609 of 5 stars
3.61.00.00.01.14.20.0
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
2.1141 of 5 stars
3.53.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Erasca, Inc. stock logo
ERAS
Erasca
3.00
Buy$4.57192.10% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
3.14
Buy$11.83123.69% Upside
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00
N/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3.00
Buy$49.33178.88% Upside

Current Analyst Ratings Breakdown

Latest TBUFF, RZLT, TRML, and ERAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Erasca, Inc. stock logo
ERAS
Erasca
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$3.00
5/14/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/30/2025
Erasca, Inc. stock logo
ERAS
Erasca
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
4/28/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/23/2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$70.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.50 per shareN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$2.19 per shareN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/A$11.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Erasca, Inc. stock logo
ERAS
Erasca
-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)

Latest TBUFF, RZLT, TRML, and ERAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12-$0.11+$0.01-$0.11N/AN/A
5/13/2025Q3 2025
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.22-$0.27-$0.05-$0.27N/AN/A
5/2/2025Q1 2025
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
-$0.91-$0.89+$0.02-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Erasca, Inc. stock logo
ERAS
Erasca
N/A
12.35
12.35
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
8.43
8.43
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
N/A
33.87
33.87

Institutional Ownership

CompanyInstitutional Ownership
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
91.89%

Insider Ownership

CompanyInsider Ownership
Erasca, Inc. stock logo
ERAS
Erasca
14.40%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.39%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/A
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120283.29 million242.49 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4085.52 million69.79 millionOptionable
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/A113.72 millionN/ANot Optionable
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4425.68 million22.35 millionOptionable

Recent News About These Companies

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
Tourmaline Bio initiated with a Buy at Chardan
Tourmaline Bio (TRML) Gets a Buy from Chardan Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

Erasca stock logo

Erasca NASDAQ:ERAS

$1.54 +0.08 (+5.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.55 +0.01 (+0.65%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$5.28 +0.31 (+6.24%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 -0.09 (-1.61%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Tribute Pharmaceuticals Canada stock logo

Tribute Pharmaceuticals Canada OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

Tourmaline Bio stock logo

Tourmaline Bio NASDAQ:TRML

$17.25 +0.97 (+5.96%)
Closing price 04:00 PM Eastern
Extended Trading
$17.26 +0.02 (+0.09%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.